[Zhejiang: Strive to achieve operating revenue of biopharmaceutical industry clusters exceeding 500 billion yuan by 2030] On September 18th, the General Office of the Zhejiang Provincial Government recently issued the "Guiding Opinions on Promoting the High-Quality Development of the Biopharmaceutical Industry" to deploy work in the next five years and propose 7 aspects and 22 measures. It is proposed that by 2030, the research and development expenses of biomedical enterprises above designated size in the province will account for about 7% of operating income, and important breakthroughs will be achieved in key common technologies and cutting-edge leading fields, and the operating income of biomedical industry clusters will exceed 500 billion yuan.